Congress moves to block drug makers' pay-for-delay deals

What it does

This bill prohibits brand-name drug and biologic manufacturers from paying generic drug makers and biosimilar manufacturers to delay market entry of cheaper alternatives. It treats such 'reverse payment' settlement agreements as unfair competition under the FTC Act, creates a legal presumption that these deals are anticompetitive, and allows the FTC to impose civil penalties up to three times the value received. The bill aims to preserve the competitive intent of the 1984 generic drug law and 2009 biosimilar law by blocking deals that keep cheaper drugs off the market longer than patent law requires.

Why we flagged it

The bill's core mechanism is a new FTC Act section creating a statutory prohibition and presumption against reverse payment settlements in pharmaceutical patent disputes. It is straightforward antitrust enforcement, not a subsidy, carve-out, or deregulation.

What the text implies

• The 30-day lookback window for 'related agreements' may capture legitimate ancillary deals (e.g., supply agreements, technology transfers) if they are contingent on or related to a patent settlement, potentially chilling legitimate business arrangements.
• The rebuttable presumption shifts burden to defendants to prove procompetitive benefits outweigh anticompetitive effects; while rebuttable, this inverts the usual antitrust burden and may increase litigation costs for smaller generic/biosimilar entrants defending their own settlements.
• The FTC's 6-year statute of limitations runs from the date of certification filing, not from discovery of the violation, potentially allowing enforcement long after parties reasonably believed a settlement was lawful.
• The bill requires CEO certification of all ancillary agreements and oral commitments within 30 days; failure to disclose or misstatement exposes executives to potential perjury liability, creating personal legal risk beyond corporate penalties.
• Forfeiture of the 180-day exclusivity period (first-filer generic advantage) for violations may disproportionately harm smaller generic manufacturers who rely on that exclusivity to recoup R&D costs.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens and public payers (Medicare, Medicaid, employers) benefit from lower drug prices and faster generic/biosimilar entry. The bill removes a mechanism by which brand manufacturers suppress competition and artificially extend monopoly pricing. The presumption of anticompetitive harm is rebuttable, preserving legitimate settlements and reasonable litigation cost recovery.

Who stands to gain

• Generic drug manufacturers (faster market entry, reduced pay-for-delay settlements)
• Biosimilar manufacturers (same competitive advantage)
• Public payers (Medicare, Medicaid, VA) and private insurers (lower drug costs)
• Consumers with high out-of-pocket drug costs

Named in the bill

Federal Trade Commission (FTC), Brand-name pharmaceutical manufacturers, Generic drug manufacturers, Biosimilar manufacturers, FDA (Food and Drug Administration), Department of Justice (Antitrust Division), Medicare, Medicaid, Patent Trial and Appeal Board (PTAB), US Patent and Trademark Office

Where it stands

8 cosponsors: 5 Democrats, 3 Republicans.

• Mar 24, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 24, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”
• Apr 3, 2025 — Reported out of committee · Congress.gov: “Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

28 lobbying clients named this bill on 43 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $32,267,914 in lobbying spend. A filing names 18 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 98% of bills with at least one filing.

Amy Klobuchar, the sponsor, reported $116,500 in PAC receipts in the 2026 cycle.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Pharmaceutical Care Management Association — $3,282,990 on 1 filing
• Blue Cross and Blue Shield Association — $2,430,000 on 2 filings
• Biotechnology Innovation Organization — $2,360,000 on 1 filing
• Kaiser Foundation Health Plan Inc — $1,420,000 on 2 filings

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.